Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health, with collaborators at La Jolla Institute for Immunology and elsewhere, have further elucidated how ovarian cancer tumors defy immunotherapy, identifying new molecular targets that might boost immune response.
The findings will publish in the April 11, 2022 online issue of PNAS.
Ovarian cancer is the fifth leading cause of cancer deaths among women and the majority of these cases are high-grade serous ovarian cancer (HGSOC) tumors, according to the American Cancer Society.
HGSOC is lethal in part because it is often resistant to chemotherapy. Immunotherapy, a therapeutic approach that uses a person’s immune system to fight disease, has been promising in many cancers, but approaches to use immunotherapy have not yet shown success in HGSOC.
One approach to immunotherapy targets proteins called checkpoint receptors that act as brakes on immune system activation. Inhibitors of checkpoint receptors release this brake, allowing the immune system to attack cancer cells. However, for immunotherapy to work effectively against HGSOC, treatments need to also disable the protective environment created by the cancer cells.
In the study led by Duygu Ozmadenci, PhD, postdoc scholar, and senior author David D. Schlaepfer, PhD, professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at UC San Diego School of Medicine, they provide new insights into the molecular details of tumor and immune cell communication and resulting dysfunction in HGSOC.
“Ovarian cancer is one of oncology’s greatest challenges,” Schlaepfer said. “Tumors can develop without obvious symptoms. The most common sign of ovarian cancer is abdominal swelling when the disease is advanced, which is when most women are diagnosed.”
Ozmadenci and colleagues found that activation of a key signaling protein within tumors called focal adhesion kinase (FAK) regulated expression of a protein called CD155 that binds to the checkpoint receptor called TIGIT on immune cells. In effect, the tumor is building a safe environment for the cancer cells to grow and evade immune detection in part by maintaining high levels of CD155 as a shield against immune attack.
In a preclinical model of aggressive ovarian cancer, the researchers found that an oral anti-FAK drug reduced CD155 and other checkpoint proteins. When used together with an immunotherapy blocking TIGIT, an elevated immune response was observed against the ovarian cancer cells. This, in turn resulted in smaller tumors and longer survival.
“Several companies are testing inhibitors to FAK and others have inhibitory antibodies to the TIGIT checkpoint receptor in clinical trials,” said Schlaepfer. “In HGSOC tumors, where high levels of CD155 and active FAK are common, our results provide compelling support for targeting FAK and TIGIT as part of a new immune-boosting therapeutic strategy.”
Co-authors include: Jayanth S. Shankara Narayanan, Jacob Andrew, Marjaana Ojalill, Allison M. Barrie, Shulin Jiang, Samhita Iyer, Thomas Bertotto, Michael Rose, Valeria Estrada, Alfredo Molinolo, Michael C. McHale, Rebekah R. White and Dwayne G. Stupack, all at UC San Diego and Moores Cancer Center; Xiao Lei Chen, Xiamen University, China; Zbigniew Mikulsi, La Jolla Institute for Immunology; Denise C. Connolly, Fox Chase Cancer Center; Jonathan A. Pachter, Verastem Oncology; and Vijay K. Kuchroo, Harvard Medical School.
Funding for this research came, in part, from the Department of Defense (grant DOD W81XWH19101), the National Institutes of Health (grants 1R01CA24756, R01CA254342, T32-CA121938, S10OD021831, P30CA23100, P01AI039671), Nine Girls Ask?, the Ovarian Cancer Research Alliance (grant OCRA 650255) and the California Institute for Regenerative Medicine (grant FA1-00607).